Jan 28, 2026 8:00am EST Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
March 3, 2025 Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids
December 20, 2023 Navigating the Future of Pain Management: Ensysce Biosciences’ Innovative Approach